# Clinical trials recruiting in Texas: 5,317 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 5,317 trials recruiting or not yet recruiting with a site in Texas, as read on November 19, 2026.

## The full list

Clinical trials recruiting in Texas: 5,317 rows for $133.17, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 104 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/state/texas

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 5,317
- Recruiting or not yet: 5,317
- Read on: November 19, 2026

## Trials

The 25 newest of 5,317, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07946679 | Leveraging Telemedicine to Improve Guideline-Directed Medical Therapy Use and Outcomes Among Rural Patients With Heart Failure | University of Michigan | Not applicable | Not yet recruiting | Heart Failure, Heart Failure Hospitalization | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07946679) |
| November 18, 2026 | NCT07944508 | A Phase 1 Study of MVB-101 Administered Intraprostatically in Patients With Localized Prostate Cancer Who Are Scheduled for Radical... | MultiValent Biotherapies, Inc. | Phase 1 | Recruiting | Localized Prostate Adenocarcinoma | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07944508) |
| November 18, 2026 | NCT07944105 | SPARK UPS/MFS: Study Of BET Inhibition With ZEN003694 To Potentiate Anti-Tumor Responses With Radiotherapy To Kickstart Abscopal Effect In... | M.D. Anderson Cancer Center | Phase 1/2 | Not yet recruiting | Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma | 57 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07944105) |
| November 18, 2026 | NCT07944079 | Acupuncture Delivery In The Clinical Decision Unit (CDU) For The Management Of Pain, Nausea, And Other Symptoms | M.D. Anderson Cancer Center | Not applicable | Not yet recruiting | Pain | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07944079) |
| November 17, 2026 | NCT07943091 | A Study of LY3945262 in Healthy Participants | Eli Lilly and Company | Phase 1 | Not yet recruiting | Healthy Volunteers | 116 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07943091) |
| November 17, 2026 | NCT07941609 | A Study to Investigate the Efficacy and Safety of Dato-DXd-based Combinations in Participants With TROP2 NMR+ NSCLC | AstraZeneca | Phase 2 | Not yet recruiting | Non-small Cell Lung Cancer (NSCLC) | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07941609) |
| November 17, 2026 | NCT07940881 | A Multicenter, Open-label, Phase 1/1b, Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SI-B037 in Solid Tumors | SystImmune Inc. | Phase 1 | Recruiting | Locally Advanced /Metastatic Solid Tumors, Locally Advanced / Metastatic Solid Tumors, First in Human, Metastatic Solid... | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07940881) |
| November 16, 2026 | NCT07940127 | AI-Driven Hip Exoskeleton Control for Diverse Users and Walking Tasks | Carnegie Mellon University | Not applicable | Recruiting | Healthy Volunteers, Gait, Aging | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07940127) |
| November 16, 2026 | NCT07939815 | A Study of BMS-986548 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies | Bristol-Myers Squibb | Phase 1/2 | Not yet recruiting | Advanced Solid Malignancies | 171 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07939815) |
| November 16, 2026 | NCT07939529 | People With Active Viremia Treated With Lenacapavir and Long-Acting Cabotegravir for Effectiveness | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 | Not yet recruiting | HIV Viremia | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07939529) |
| November 16, 2026 | NCT07938073 | Phase 2 Study Of IDH 1/2 Inhibitor Vorasidenib In Patients With IDH2-Mutated Intrahepatic Cholangiocarcinoma | M.D. Anderson Cancer Center | Phase 2 | Not yet recruiting | IDH2-Mutated Intrahepatic Cholangiocarcinoma | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07938073) |
| November 16, 2026 | NCT07937696 | A Vaccine (Nous-209) for the Reduction of Colorectal Lesion Size in Patients With Lynch Syndrome | National Cancer Institute (NCI) | Phase 2 | Not yet recruiting | Colorectal Carcinoma, EPCAM Lynch Syndrome, Lynch Syndrome, MLH1 Lynch Syndrome, MSH2 Lynch Syndrome, MSH6 Lynch... | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07937696) |
| November 13, 2026 | NCT07935356 | A Phase 3 Evaluation of Sutacimig in Glanzmann Thrombasthenia | Sponsor not shown (see the record) | Phase 3 | Recruiting | Thrombasthenia | 76 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07935356) |
| November 13, 2026 | NCT07935317 | A Study of Tersolisib (LY4064809) and Abemaciclib With Hormone Therapies in Participants With PIK3CA-Mutated Early Breast Cancer | Eli Lilly and Company | Phase 2 | Not yet recruiting | Breast Neoplasms | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07935317) |
| November 12, 2026 | NCT07934329 | CCS Transitions to Adult Care | University of Texas Southwestern Medical Center | Not applicable | Not yet recruiting | Childhood Cancer Survivors, Adolescent and Young Adult Cancer Survivors, Primary Care | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07934329) |
| November 12, 2026 | NCT07934264 | \[18F\]ZDG2 First-in-Human PET Imaging in PAH | The Methodist Hospital Research Institute | Early phase 1 | Not yet recruiting | Pulmonary Artery Hypertension | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07934264) |
| November 12, 2026 | NCT07934108 | Impact of Community-based Boxing Exercises in Individuals With Chronic Stroke | Texas Woman's University | Not applicable | Recruiting | Stroke Chronic | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07934108) |
| November 12, 2026 | NCT07933549 | REstoration of Communication and LAnguage With Intracortical Microelectrodes | The University of Texas Health Science Center, Houston | Not applicable | Not yet recruiting | Amyotrophic Lateral Sclerosis (ALS), locked-in Syndrome, Brain Injury, Stroke | 4 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07933549) |
| November 12, 2026 | NCT07932652 | Increasing Mothers' Own Milk Feeding in the Neonatal ICU | The University of Texas Health Science Center, Houston | Not applicable | Recruiting | Mothers' Own Milk Feeding, Cessation or Non-initiation of Mothers' Own Milk Feeding | 1,176 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07932652) |
| November 12, 2026 | NCT07931690 | IMPACT-Ready Study | Sponsor not shown (see the record) | Observational | Not yet recruiting | Autism Spectrum Disorder, Neurodevelopmental Disorders | 1,250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07931690) |
| November 12, 2026 | NCT07931599 | A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Diabetes Mellitus, Type 2 | 1,060 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07931599) |
| November 12, 2026 | NCT07931573 | AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Type 2 Diabetes | 1,200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07931573) |
| November 12, 2026 | NCT07931547 | A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Type 2 Diabetes, Chronic Kidney Disease | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07931547) |
| November 12, 2026 | NCT07931534 | Pediatric Adeno-Tonsillar Hypertrophy Treatment Post-Approval Study | ENTire Medical Ltd. | Not applicable | Not yet recruiting | Airway Obstruction Upper, Tonsillectomy, Adenoidectomy Surgery, Hypertrophy | 73 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07931534) |
| November 12, 2026 | NCT07931495 | A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Diabetes Mellitus, Type 2 | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07931495) |

## Sites with the most of these trials

Sites as the records name them, organizations only.

| Site | City | Trials |
| --- | --- | --- |
| MD Anderson Cancer Center | Houston | 407 |
| M D Anderson Cancer Center | Houston | 241 |
| University of Texas Southwestern Medical Center | Dallas | 197 |
| Baylor College of Medicine | Houston | 196 |
| UT Southwestern Medical Center | Dallas | 186 |
| The University of Texas Health Science Center at Houston | Houston | 186 |
| The University of Texas MD Anderson Cancer Center | Houston | 150 |
| Houston Methodist Hospital | Houston | 132 |
| Texas Children's Hospital | Houston | 106 |
| UT MD Anderson Cancer Center | Houston | 97 |
| University of Texas Health Science Center at San Antonio | San Antonio | 91 |
| University of Texas MD Anderson Cancer Center | Houston | 90 |
| UT Southwestern/Simmons Cancer Center-Dallas | Dallas | 85 |
| The University of Texas M. D. Anderson Cancer Center | Houston | 84 |
| NEXT Oncology | San Antonio | 69 |
| University of Texas Southwestern | Dallas | 66 |
| Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center | Houston | 63 |
| Cook Children's Medical Center | Fort Worth | 61 |
| Baylor University Medical Center | Dallas | 45 |
| University of Texas Medical Branch | Galveston | 43 |
| Dell Children's Medical Center of Central Texas | Austin | 36 |
| UT Southwestern Clinical Center at Richardson/Plano | Richardson | 35 |
| Parkland Memorial Hospital | Dallas | 34 |
| UT Southwestern/Simmons Cancer Center-Fort Worth | Fort Worth | 33 |
| Texas Oncology | Dallas | 33 |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 51 |
| Phase 1 | 701 |
| Phase 1/2 | 507 |
| Phase 2 | 939 |
| Phase 2/3 | 121 |
| Phase 3 | 948 |
| Phase 4 | 145 |
| Not applicable | 1,131 |
| Observational | 774 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Carcinoma, Non-Small-Cell Lung | 237 |
| Neoplasms | 217 |
| Breast Neoplasms | 189 |
| Colorectal Neoplasms | 160 |
| Neoplasm Metastasis | 154 |
| Prostatic Neoplasms | 125 |
| Ovarian Neoplasms | 125 |
| Lung Neoplasms | 112 |
| Leukemia, Myeloid, Acute | 103 |
| Endometrial Neoplasms | 103 |
| Obesity | 98 |
| Pancreatic Neoplasms | 90 |
| Melanoma | 83 |
| Recurrence | 78 |
| Squamous Cell Carcinoma of Head and Neck | 78 |
| Diabetes Mellitus, Type 2 | 71 |
| Stomach Neoplasms | 70 |
| Heart Failure | 70 |
| Triple Negative Breast Neoplasms | 66 |
| Overweight | 66 |
| Carcinoma, Renal Cell | 61 |
| Multiple Myeloma | 59 |
| Urinary Bladder Neoplasms | 56 |
| Stress Disorders, Post-Traumatic | 56 |
| Carcinoma, Hepatocellular | 53 |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| M.D. Anderson Cancer Center | 574 |
| The University of Texas Health Science Center, Houston | 186 |
| University of Texas Southwestern Medical Center | 178 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 107 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 101 |
| Baylor College of Medicine | 89 |
| The University of Texas Health Science Center at San Antonio | 85 |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 71 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 65 |
| National Cancer Institute (NCI) | 62 |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 59 |
| [AbbVie](https://specstream.ai/data/clinical-trials/company/abbvie) | 58 |
| [Bristol-Myers Squibb](https://specstream.ai/data/clinical-trials/company/bristol-myers-squibb) | 52 |
| The Methodist Hospital Research Institute | 50 |
| University of Texas at Austin | 48 |
| [GlaxoSmithKline](https://specstream.ai/data/clinical-trials/company/glaxosmithkline) | 46 |
| VA Office of Research and Development | 46 |
| [Janssen Research & Development, LLC](https://specstream.ai/data/clinical-trials/company/janssen-research-and-development-llc) | 43 |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 41 |
| [Sanofi](https://specstream.ai/data/clinical-trials/company/sanofi) | 35 |
| [Hoffmann-La Roche](https://specstream.ai/data/clinical-trials/company/hoffmann-la-roche) | 34 |
| [Boehringer Ingelheim](https://specstream.ai/data/clinical-trials/company/boehringer-ingelheim) | 33 |
| Baylor Research Institute | 32 |
| The University of Texas Medical Branch, Galveston | 32 |
| [Novo Nordisk A/S](https://specstream.ai/data/clinical-trials/company/novo-nordisk-a-s) | 30 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in Texas

- [Furniture manufacturers in Texas, United States](https://specstream.ai/data/businesses/furniture-manufacturers/texas-united-states)
- [Accounting firms in Texas, United States](https://specstream.ai/data/businesses/accounting-firms/texas-united-states)
- [Maternity centers in Texas, United States](https://specstream.ai/data/businesses/maternity-centers/texas-united-states)
- [Cheesesteak restaurants in Texas, United States](https://specstream.ai/data/businesses/cheesesteak-restaurants/texas-united-states)
- [Public schools in Texas, United States](https://specstream.ai/data/businesses/public-schools/texas-united-states)
- [Farm equipment suppliers in Texas, United States](https://specstream.ai/data/businesses/farm-equipment-suppliers/texas-united-states)
